STAAR Surgical’s third quarter was marked by a favorable market reaction after revenue and profits exceeded Wall Street’s expectations, even as headline sales declined year over year. Management attributed the results to robust demand for its EVO+ and toric lenses, particularly in China, where product mix and pricing powered growth despite supply constraints. CEO Warren Foust noted the company’s progress in shifting manufacturing to Switzerland, which helped mitigate tariff impacts and improve supply chain resilience. The company also highlighted broader adoption across mid-tier hospitals and sustained expansion in key international markets.

Is now the time to buy STAA? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from STAAR Surgical’s Q3 earnings call

• Tom Stephan (Stifel) asked about China inventory dynamics and the supply-demand balance. CEO Warren Foust clarified that inventory declines resulted from strong in-market demand and supply limitations, emphasizing the complexity of manufacturing polymer-based lenses.
• John Young (Canaccord) inquired about potential restocking and unmet demand in China. Foust responded that no significant restocking is expected, as current inventory levels closely match targets and supply shortfalls were limited.
• Anthony Petrone (Mizuho Group) questioned visibility into the China sales pipeline and U.S. market expansion channels. Foust highlighted strong demand from major partners and discussed potential for broader U.S. adoption through both large refractive centers and emerging vertical integration trends.
• Young Li (Jefferies) requested updates on EVO+ penetration in China and expectations for further adoption. Foust noted high growth in lower diopter units and expansion into mid-tier and public hospitals, indicating further runway for penetration.
• Ryan Zimmerman (BTIG) pressed on pricing durability and end-market demand in China. Foust explained that higher ASPs are sustainable due to the popularity of toric and V5 lenses, and emphasized continued growth opportunity as supply improves.

Catalysts in upcoming quarters

In upcoming quarters, the StockStory team will monitor (1) the pace of manufacturing yield improvements and whether Swiss facility capacity meets rising demand, (2) progress on first-in-human trials for presbyopia lenses and any subsequent regulatory milestones, and (3) sustained growth in key regions outside China, especially in the U.S. and EMEA. Ongoing management of supply chain constraints and product mix will also be key indicators of execution.

STAAR Surgical currently trades at $26.82, down from $27.17 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.